Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl} sulfonamides

Journal of Medicinal Chemistry

Volumn 50, Issue 7, 2007, Pages 1546-1557

  Chan, Chuen ^a   Borthwick, Alan D ^a   Brown, David ^a   Burns Kurtis, Cynthia L ^b   Campbell, Matthew ^a   Chaudry, Laiq ^a   Chung, Chun Wa ^a   Convery, Máire A ^a   Hamblin, J Nicole ^a   Johnstone, Lisa ^a   Kelly, Henry A ^a   Kleanthous, Savvas ^a   Patikis, Angela ^a   Patel, Champa ^a   Pateman, Anthony J ^a   Senger, Stefan ^a   Shah, Gita P ^a   Toomey, John R ^b   Watson, Nigel S ^a   Weston, Helen E ^a   Whitworth, Caroline ^a   Young, Robert J ^a   Zhou, Ping ^a   more..

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (5 CHLOROTHIEN 2 YL) N [1 (1 METHYL 2 MORPHOLIN 4 YL 2 OXOETHYL) 2 OXOPYRROLIDIN 3 YL]ETHENESULFONAMIDE; BLOOD CLOTTING FACTOR 10A INHIBITOR; HUMAN SERUM ALBUMIN; LIGAND; N [1 (1 METHYL 2 MORPHOLIN 4 YL 2 OXOETHYL) 2 OXOPYRROLIDIN 3 YL]SULFONAMIDE; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CRYSTAL STRUCTURE; DOG; DRUG BINDING; DRUG DISTRIBUTION; DRUG HALF LIFE; LIPOPHILICITY; MOLECULAR MODEL; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTICOAGULANTS; CRYSTALLOGRAPHY, X-RAY; DOGS; FACTOR XA; FEMALE; HUMANS; LIGANDS; MALE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MORPHOLINES; PROTEIN BINDING; PROTHROMBIN TIME; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 34147108048     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060870c     Document Type: Article

References (82)

1. Fevig, J. M.; Wexler, R. R. Anticoagulants: Thrombin and Factor Xa Inhibitors. Annu. Rep. Med. Chem. 1999, 34, 81-100.
2. Zhu, B.-Y.; Scarborough, R. M. Factor Xa Inhibitors: Recent Advances In Anticoagulant Agents. Annu. Rep. Med. Chem. 2000, 35, 83-102.
3. Scarborough, R. M.; Pandey, A.; Zhang, X. Small Molecule Anticoagulant/Antithrombotic Agents. Annu. Rep. Med. Chem. 2005, 40, 85-101.
4. Linkins, L.-A.; Weitz, J. I. New Anticoagulants. Semin. Thromb. Hemostasis 2003, 29 (6), 619-663.
5. Hirsh, J.; Warkentin, T. E.; Raschke, R.; Granger, C.; Ohman, E. M.; Dalen, J. E. Heparin and Low-Molecular-Weight Heparin: Mechanism of Action. Pharmacokinetics. Dosing Considerations, Monitoring, Efficacy, and Safety. Chest 1998, 114 (5), 489S-510S.
6. Hirsh, J.; Dalen, J. E.; Anderson, D. R.; Poller, L.; Bussey, H.; Ansell. J.; Deykin, D.; Brandt, J. T. Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range. Chest 1998, 114 (5), 445S-469S.
7. Davie, E. W.; Fujikawa, K.; Kisiel, W. The Coagulation Cascade: Initiation, Maintenance, and Regulation. Biochemistry 1991, 30 (43), 10363-10370.
8. (a) Connolly, A. J.; Ishihara, H.; Kahn, M. L.; Farese, R. V., Jr.; Coughlin, S. R. Role of the Thrombin Receptor in Development and Evidence for a Second Receptor. Nature 1996, 381 (6582), 516-519.
9. (b) Kaiser, B. Factor Xa-A Promising Target for Drug Development. Cell. Mol. Life Sci. 2002, 59 (2), 189-192.
10. (c) Alexander, J. H.; Singh, K. P. Inhibition of Factor Xa: A Potential Target for the Development of New Anticoagulants. Am. J. Cardiovasc. Drugs 2005, 5 (5), 279-290.
11. (d) Kubitza, D.; Haas, S. Novel Factor Xa Inhibitors for Prevention and Treatment of Thromboembolic Diseases. Exp. Opin. Invest. Drugs 2006, 15 (8), 843-855.
12. (a) Decousus, H.; Rivron-Guillot, K.; Girard, G.; Moulin, N. Clinical Efficacy and Safety of Fondaparinux in the Prevention and Treatment of Venous and Arterial Thrombosis. Future Cardiol. 2005, 1 (6), 743-758.
13. (b) Bauersachs, R. M. Fondaparinux: An Update on New Study Results. Eur. J. Clin. Investig. 2005, 35 (Suppl. 1), 27-32.
14. (c) Arixtra gets EU approval for VTE (venous thromboembolism) prophylaxis in major orthopaedic surgery. Scrip; 20th Nov 2003; No. 2860, p 27.
15. (d) Expanded U.S. approval for Arixtra in hip fracture surgery. Scrip; 20th Jun 2003; No. 2748, p 22.
16. (a) Eriksson, B. Clinical Experience with Ximelagatran in Orthopedic Surgery. Drugs 2004, 64 (Suppl. 1 ), 27-35.
17. (b) Boos, C. J.; Hinton, A.; Lip, G. Y. H. Ximelagatran: A Clinical Perspective. Eur. J. Intern. Med. 2005, 16 (4), 267-278.
18. (c) Quan, M. L.; Lam, P. Y. S.; Han, Q.; Pinto, D. J. P.; He, M. Y.; Li, R.; Ellis, C. D.; Clark, C. G.; Teleha, C. A.; Sun, J.-H.; Alexander, R. S.; Bai, S.; Luettgen, J. M.; Knabb, R. M.; Wong, P. C.; Wexler, R. R. Discovery of 1-(3′-Aminobenzisoxazol-5′-yl)-3-trifluoromethyl-N-[2-fluoro- 4-[(2′-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5- carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor. J. Med. Chem. 2005, 48 (6), 1729-1744.
19. (d) Eriksson, B. I.; Quinlan, D. J. Oral Anticoagulants in Development: Focus on Thromboprophylaxis in Patients Undergoing Orthopaedic Surgery. Drugs 2006, 66 (11), 1411-1429.
20. (e) (i) Study backs controversial blood-thinning drug. Reuters News; 08 Feb 2005. (ii) More bad news for Exanta as France requests more data. Scrip: 20 Jan 2005.
21. Dabigatran etexilate (currently in phase III): (a) Sorbera, L. A.; Bozzo, J.; Castaner, J. Dabigatran/Dabigatran Etexilate: Prevention of DVT Prevention of Ischemic Stroke Thrombin Inhibitor. Drugs Future 2005, 30 (9), 877-885.
22. (b) Slangier, J.; Eriksson, B. I.; Dahl, O. E.; Ahnfelt, L.; Nehmiz, G.; Staehle, H.; Rathgen, K.; Svaerd, R. Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement. J. Clin. Pharmacol. 2005. 45 (5), 555-563.
23. (c) Boehringer Ingelheim launches REVOLUTION program for dabigatran etexilate. Prous; 20th Jan 2006. MCC-977 (no structure or CAS number available, currently in phase II):
24. (d) MCC-977 - Mitsubishi Pharma (JP): Phase II Clinical Trial. Pharmaprojects; 18th May 2006.
25. Rivaroxaban (BAY -59 - 7939; currently in phase III): (a) Eriksson, B. I.; Borris, L.; Dahl, O. E.; Haas, S.; Huisman, M. V.; Kakkar, A. K.; Misselwitz, F.; Kaelebo, P. Oral, Direct Factor Xa Inhibition with BAY-59-7939. For the Prevention of Venous Thromboembolism after Total Hip Replacement. J. Thromb. Haemost. 2006, 4(1), 121-128.
26. (b) Roehrig, S.; Straub, A.; Pohlmann, J.; Lampe, T.; Pernerstorfer, J.; Schlemmer, K.-H.; Reinemer, P.; Perzborn, E. Discovery of the Novel Antithrombotic Agent 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59 - 7939): An Oral. Direct Factor Xa Inhibitor. J. Med. Chem. 2005, 48 (19), 5900-5908,
27. LY-517717 (N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1- piperazinyl]-2-oxo-1-phenyl-ethyl]-1H-Indole-6-carboxamide, CAS number 313489-71-3, currently in Phase II): (c) LY-517717: A Novel Prophylactic for VTE following Major Orthopedic Surgery. Prous; 02 Jan 2006.
28. (d) Saiah, E.; Soares, C. Small Molecule Coagulation Cascade Inhibitors in the Clinic. Curr. Top. Mad. Chern. 2005, 5 (16), 1677-1695.
29. DU-176b (CAS number 912273-65-5, no structure available): (e) Daiichi Sankyo (JP): Phase II Clinical Trial. Pharmaprojects; 03 Apr 2006.
30. (f) Cardiovasculars Take Centre Stage in Daiichi-Sankyo's R&D Plan.
31. Scrip; 30 Mar 2006.
32. Apixaban: (g) Apixaban Enters Phase II/III Trials as a Preventive Therapy for Venous and Pulmonary Thrombosis.
33. Prous; 16 Sep 2005. DX-9065a ([S-(R*, R*)]-7-(Aminoimi nomethyl)-α-[4-[[1-(1-iminoethyl)-3- pyrrolidinyl]oxy]phenyl]-2-naphthalenepropanoic Acid, Monohydrochloride, Pentahydrate,
34. CAS number 155204-81-2, currently in Phase II): (h) Kaiser, B. DX-9065a Daiichi. Curr. Opin. Invest. Drugs 2003, 4 (9). 1105- 1112.
35. (i) Daiichi Sankyo (JP): Phase II Clinical Trial. Pharmaprojects; Monday, 24 Jul 2006.
36. Watson, N. S.; Pass, M.; Patel, V. Preparation of 5-[2-(Pyridin-4- ylamino)ethoxy]benzamides as Thrombin Inhibitors. PCT Int. Appl. 1997, p 139, WO9722589A1; Chem. Abstr. 1997, 127, 121643.
37. (a) Ewing, W. R.; Becker, M. R.; Manetta, V. E.; Davis, R. S.; Pauls. H. W.; Mason, H.; Choi-Sledeski, Y. M.; Green, D.; Cha, D.; Spada, A. P.; Cheney, D. L.; Mason, J. S.; Maignan, S.; Guilloteau, J.-P.; Brown, K.; Colussi, D.: Bentley, R.; Bostwick, J.; Kasiewski, C. J.; Morgan, S. R.; Leadley, R. J.; Dunwiddie, C. T.; Perrone, M. H.; Chu, V. Design and Structure-Activity Relationships of Potent and Selective Inhibitors of Blood Coagulation Factor Xa. J. Med. Chem. 1999, 42, 3557-3571.
38. (b) Watson, N. S.; Brown, D.; Campbell, M.; Chan, C.; Chaudry, L.; Convery, M. A.; Fenwick, R.; Hamblin, J. N.; Haslam, C.; Kelly, H. A.; King, N. P.; Kurtis, C. L.; Leach, A. R.; Manchee, G.; Mason, A. M.; Mitchell, C.; Patel, C.; Patel, V. K.; Senger, S.; Shah, G. P.; Weston, H. E.; Whitworth, C.; Young, R. J. Design and Synthesis of Orally Active Pyrrolidin-2-one-based Factor Xa Inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 3784-3788.
39. Mac-Donald, S. J. F.; Clarke, G. D. E.; Dowle, M. D.; Harrison, L. A.; Hodgson, S. T.; Inglis, G. G. A.; Johnson, M. R.; Shah, P.; Upton, R. J.; Walls, S. B. A Flexible, Practical, and Stereoselective Synthesis of Enantiomerically Pure trans-5-Oxohexahydropyrrolo[3,2-b]pyrroles (Pyrrolidine-trans-lactams), a New Class of Serine Protease Inhibitors. Using Acyliminium Methodology. J. Org. Chem. 1999, 64, 5166-5175.
40. (a) For 6a: Haginoya, N.; Kobayashi, S.; Komoriya, S.; Yoshino, T.; Suzuki, M.; Shimada, T.; Watanabe, K.; Hirokawa, Y.; Furugori, T.; Nagahara, T. Synthesis and Conformational Analysis of a Non-Amidine Factor Xa Inhibitor That Incorporates 5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 Binding Element. J. Med. Chem. 2004, 47(21), 5167-5182.
41. (b) For 6c: Matier, W. L.; Comer, W. T.; Gomoll, A. W. Synthesis and Biological Properties of 5-Aryl-4H-1,2,4-thiadiazine 1,1-Dioxides. J. Med. Chem. 1974, 17(5), 549-552.
42. (c) For 6f: Choi-Sledeski, Y. M.; Kearney, R.; Poli, G.; Pauls, H.; Gardner, C.; Gong, Y.; Becker, M.; Davis, R.; Spada, A.; Liang, G.; Chu, V.; Brown, K.; Collussi, D.; Leadley, R., Jr.; Rebello, S.; Moxey, P.; Morgan, S.; Bentley, R.; Kasiewski, C.; Maignan, S.; Guilloteau, J.-P.; Mikol, V. Discovery of an Orally Efficacious Inhibitor of Coagulation Factor Xa which Incorporates a Neutral P1 Ligand. J. Med. Chem. 2003, 46 (5), 681-684.
43. (d) For 6g: Ando, T.; Saito, Y.; Yamawaki, J.; Morisaki, H.; Sawada, M.; Yukawa, Y. 6-Methyl-2-naphthalenesulfonate (menasylate). New and Useful Leaving Group for Trifluoroacetolysis. J. Org. Chem. 1974, 39(16), 2465-2466.
44. For 6b, 6d, 6e, and 6j: Ewing, W. R.; Becker, M. R.; Choi-Sledeski, Y. M.; Pauls, H. W.; McGarry, D. G.; Davis, R. S.; Spada, A. Preparation of Heterocyclylsulfonylaminooxopyrrolidinylmethyl-benzamidines and Related Compounds as Factor Xa Inhibitors. 1998, p 36, U.S. Patent 5,731,315A; Chem. Abstr. 1998, 128, 243948.
45. (a) For 6k: Chan, C.; Hamblin, J. N.; Kelly, H. A.; King, N. P.; Mason, A. M.; Patel, V. K.; Senger, S.; Shah, G. P.; Watson, N. S.; Weston, H. E.; Whitworth, C.; Young, R. J. Preparation of 3-Sulfonylaminopyrrolidine-1- acetamides as Factor Xa Inhibitors. PCT Int. Appl. 2002, p 85, WO2002100830A; Chem. Abstr. 2002, 138, 39537.
46. (b) For 6I: Choi-Sledeski, Y. M.; Pauls, H. W.; Barton, J. N.; Ewing, W. R.; Green, D. M.; Becker, M. R. Preparation of Sulfonic Acid or Sulfonylamino N-(Heteroaralkyl)-azaheterocyclylamide Compounds as Inhibitors of Factor Xa. PCT Int. Appl. 1998, p 116. WO9825611A; Chem. Abstr. 1998, 129, 81744.
47. For 6o and 6p: Komoriya, S.; Haginoya, N.; Kobayashi, S.; Nagata, T.; Mochizuki, A.; Suzuki, M.; Yoshino, T.; Horino, H.; Nagahara, T.; Suzuki, M.; Isobe, Y.; Furugoori, T. Design, Synthesis, and Biological Activity of Nonbasic Compounds as Factor Xa Inhibitors: SAR Study of S1 and Aryl Binding Sites. Bioorg. Med. Chem. 2005, 13 (12), 3927-3954.
48. For Boc-6s and Boc-6t: (a) Jia, Z. J.; Su, T.; Zuckett, J. F.; Wu, Y.; Goldman, E. A.; Li, W.; Zhang, P.; Clizbe, L. A.; Song, Y.; Bauer, S. M.; Huang, W.; Woolfrey, J.; Sinha, U.; Arfsten, A. E.; Hutchaleelaha, A.; Hollenbach, S. J.; Lambing, J. L.; Scarborough, R. M.; Zhu, B.-Y. N,N-Dialkylated 4-(4-Arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-Arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as Potent Factor Xa Inhibitors. Bioorg. Med. Chem. Lett. 2004, 14 (9), 2073-2078.
49. (b) Ewing, W. R.; Becker, M. R.; Choi-Sledeski, Y. M.; Pauls, H. W.; He, W.; Condon, S. M.; Davis, R. S.; Hanney, B. A.; Spada, A. P.; Burns, C. J.; Jiang, J. Z.; Li, A.; Myers, M. R.; Lau, W. F.; Poli G.B. Substituted Piperazinone Derivatives and other Oxoazaheterocyclyl Compounds Useful as Factor Xa/IIa Inhibitors. PCT Int. Appl. 2001, p460, WO2001007436A; Chem. Abstr. 2001, 134, 163059.
50. Yamamoto, T.; Zhou, Z.-H.; Kanbara, T.; Shimura, M.; Kizu, K.; Maruyama, T.; Nakamura, Y.; Fukuda, T.; Lee, B.-L.; Ooba, N.; Tomaru, S.; Kurihara, T.; Kaino, T.; Kubota, K.; Sasaki, S. π-Conjugated Donor-Acceptor Copolymers Constituted of π-Excessive and π-Deficient Arylene Units. Optical and Electrochemical Properties in Relation to CT Structure of the Polymer. J. Am. Chem. Soc. 1996, 118, 10389-10399.
51. (a) 5-Bromothiazole was prepared by monodebromination of 2,5-dibromothiazole using a procedure in: Dondoni, A.; Mastellari, A. R.; Medici, A.; Negrini, E.; Pedrini, P. Synthesis of Stannylthiazoles and Mixed Stannylsilylthiazoles and their Use for a Convenient Preparation of Mono- and Bishalothiazoles. Synthesis 1986, 9, 757-760.
52. (b) Urch, C. J.; Salmon, R.; Lewis, T.; Godfrey, C. R. A.; Clough, M. S. Preparation of 3-Aryl-3-cyano-8-azabicyclo[3.2.1]-octanes as Insecticides and Acaricides. PCT Int. Appl. 1996, p 77, WO9637494A1; Chem. Abstr. 1997, 126, 104021.
53. Saramet, I.; Banciu, M. D.; Draghici, C. Synthesis and Characterization of Some 5-Substituted-3-Mercapto-1,2,4-Triazoles. Rev. Roum. Chim. 1991, 36, 135-144.
54. (a) Attempts to prepare the sulfonyl chloride 6q by oxidation of 6-chloro-1,3-benzothiazole-2(3H)-thione with chlorine in acetic acid followed by sulfonylation with 2 gave very little desired sulfonamide (1q).
55. (b) Recently, Vedejs and Kongkittingam have shown that the stability of benzothiazole-2-sulfonyl chloride in solution could be extended with 2,6-di-t-butyl-4-methylphenol: Vedejs, E.; Kongkittingam, C. Solution-Phase Synthesis of a Hindered N-Methylated Tetrapeptide Using Bts-Protected Amino Acid Chlorides: Efficient Coupling and Methylation Steps Allow Purification by Extraction. J. Org. Chem. 2000, 65, 2309-2318.
56. (a) Pays, M.; Beljean, M. Heterocyclic Hydrazines and Hydrazones. I. Synthesis of 2-Hydrazinobenzothiazoles, 2-Hydrazmonaphtho[1,2-d]- and -[2,1-d]thiazoles and 3-Methyl-2-benzothiazolinone and 3-Methyl-2-naphthothiazolinone Hydrazones. Bull. Soc. Chim. Fr. 1973, 11 (Pt. 2), 3044-3051.
57. (b) Baudin, J. B.; Hareau, G.; Julia, S. A.; Lorne, R.; Ruel, O. Stereochemistry of Direct Olefin Formation from Carbonyl Compounds and Lithiated Heterocyclic Sulfones. Bull. Soc. Chim. Fr. 1993, 130, 856-878.
58. Masuda, Y.; Hoshi, M.; Arase, A. Simple Stereospecific Syntheses of (E)-1-Chloro(or bromojalk-1-enes from Alk-1-ynes via Hydroboration. J. Chem. Soc., Perkin Trans. 1 1992, 21, 2725-2726.
59. Maignan, S.; Guilloteau, J.-P.; Choi-Sledeski, Y. M.; Becker, M. R.; Ewing, W. R.; Pauls, H. W.; Spada, A. P.; Miko, V. Molecular Structures of Human Factor Xa Complexed with Ketopiperazine Inhibitors: Preference for a Neutral Group in the S1 Pocket. J. Med. Chem. 2003, 46, 685-690.
60. Mederski, W. W. K. R.; Cezanne, B.; van Amsterdam, C.; Buhring, K. U.; Dorsch, D.; Gleitz, J.; Marz, J.; Tsaklakidis, C. Chlorothiophenecarboxamides as P1 Surrogates of Inhibitors of Blood Coagulation Factor Xa. Bioorg. Med. Chem. Lett. 2004, 14 (23), 5817-5822.
61. (a) Gabriel, B.; Stubbs, M. T.; Bergner, A.; Hauptmann, J.; Bode, W.; Stuerzebecher, J.; Moroder, L. Design of Benzamidine-Type Inhibitors of Factor Xa. J. Med. Chem. 1998, 41 (22), 4240-4250.
62. (b) Katakura, S.; Nagahara, T.; Hara, T.; Iwamoto, M. A Novel Factor Xa Inhibitor: Structure-Activity Relationships and Selectivity between Factor Xa and Thrombin. Biochem. Biophys. Res. Commun. 1993, 197, 965-972.
63. (c) Nar, H.; Bauer, M.; Schmid, A.; Stassen, J.-M.; Wienen, W.; Priepke, H. W. M.; Kauffmann, I. K.; Ries, U. J.; Hauel, N. H. Structural Basis for Inhibition Promiscuity of Dual Specific Thrombin and Factor Xa Blood Coagulation Inhibitors. Structure 2001, 9, 29-37.
64. (d) Fevig, J. M.; Pinto, D. J.; Han, Q.; Quan, M. L.; Pruitt, J. R.; Jacobson, I. C.; Galemmo, R. A., Jr.; Wang, S.; Orwat, M. J.; Bostrom, L. L.; Knabb, R. M.; Wong, P. C.; Lam, P. Y. S.; Wexler, R. R. Synthesis and SAR of Benzamidine Factor Xa Inhibitors Containing a Vicinally-Substituted Heterocyclic Core. Bioorg, Med. Chem. Lett. 2001, 11 (5), 641-645.
65. Chung, C.-W. Personal communication.
66. Levell, J. R.; Pauls, H. W.; Choi, Y.-M.; Ewing, W. R.; Becker, M. R.; McGarry, D. G.; Gardner, C. J.; Poli, G. B.; Czekaj, M.; Gong, Y.; Li, A.-W.; Davies, R.; Jiang, J. Z.; Chu, F.-H. V.; Maignan, S.; Mikol, V.; Liang, G.-Y. Aminoquinazoline, Aminoquinoline and Aminoisoquinoline Substituted 3(R)- and 3(S)-Aminopyrrolidin-2-one Derived Factor Xa Inhibitors; 226th ACS National Meeting, New York, United States, September 7-11, 2003, MEDI-077 (for example. RPR256580 in this poster).
67. Raos, G.; Famulari, A.; Marcon, V. Computational Reinvestigation of the Bithiophene Torsion Potential. Chem. Phys. Lett. 2003, 379, 364-372.
68. Details of ab initio calculations and selected electrostatic potential maps of N-methyl chloro(hetero)arylsulfonamides, truncated structures of 1, are available in Supporting Information.
69. (a) Cappelli, A.; Giorgi, G.; Anzini, M.; Vomero, S.; Ristori, S.; Rossi, C.; Donati, A. Characterization of Persistent Intramolecular C-H⋯ X(N,O) Bonds in Solid State and Solution. Chem.-Eur. J. 2004, 10 (13), 3177-3183.
70. (b) Manikandan, K.; Ramakumar, S. The Occurrence of C-H⋯O Hydrogen Bonds in α-Helices and Helix Termini in Globular Proteins. Proteins: Struct., Funct., Bioinf. 2004, 56 (4), 768-781.
71. (c) Pierce, A. C.; Sandretto, K. L.; Bemis, G. W. Kinase Inhibitors and the Case for C-H⋯O Hydrogen Bonds in Protein-Ligand Binding. Proteins 2002, 49 (4), 567-576.
72. Senger, S.; Convery, M. A.; Chan, C.; Watson, N. S. Arylsulfonamides: A Study of the Relationship between Activity and Conformational Preferences for a Series of Factor Xa inhibitors. Bioorg. Med. Chem. Lett. 2006, 16 (22), 5731-5735.
73. Valko, K.; Nunhuck, S.; Bevan, C.; Abraham, M. H.; Reynolds, D. P. Fast Gradient HPLC Method to Determine Compounds Binding to Human Serum Albumin. Relationships with Octanol/Water and Immobilized Artificial Membrane Lipophilicity. J. Pharm. Sci. 2003, 92 (11), 2236-2248.
74. Toomey, J. R.; et al. Manuscript in preparation, 2007.
75. RPR128515 is (αR)-3-(aminoiminomethyl)-α-[(1R)-1- [[[3′-(aminomethyl)[1,1′-biphenyl]-4-yl]carbonyl]amino]ethyl] -benzenepropanoic acid, methyl ester and has a CAS number of 296761-71-2. Maignan, S.; Guilloteau, J.-P.; Pouzieux, S.; Choi-Sledeski, Y. M.; Becker, M. R.; Klein, S. I.; Ewing, W. R.; Pauls, H. W.; Spada, A. P.; Mikol, V. Crystal Structures of Human Factor Xa Complexed with Potent Inhibitors. J. Med. Chem. 2000, 43, 3226-3232.
76. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods Enzymol. 1997, 276, 307-326.
77. Leslie, A. G. W. Recent Changes to the MOSFLM Package for Processing Film and Image Plate Data; Joint CCP4 and ESF-EAMCB Newsletter on Protein Crystallography; Daresbury Laboratory: Warrington, U.K., 1992; No. 26.
78. Collaborative Computational Project, Number 4. The CCP4 Suite: Programs for Protein Crystallography. Acta Crystallogr. 1994, D50, 760-763.
79. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of Macromolecular Structures by the Maximum-Likelihood Method. Acta Crystallogr. 1997, D53, 240-255.
80. Santoro, S. A.; Eby, C. S. Laboratory Evaluation of Hemostatic Disorders. In Hematology-Basic Principles and Practice; Benz, E. J., Cohen, H. J., Furie, B., Hoffman, R., McGlave, P., Shattil, S. J., Silberstein, L. E., Eds.; Churchill Livingstone: Philadelphia, 2000; pp 1841-1842.
81. 50 curve in which there is no symmetric side for large values of X. This model is based on the modified Freundlich model with proportional weighting (larger values have less weight): y = a + (b × (X∧c)), where y is the fold-increase in time to clot formation, a is the Y offset (initial parameter estimate of 1), b is the rate scalar and orientation, X is the compound concentration, and c is the power factor.
82. These molecular graphics were generated using DeLano's PyMOL software available from http://www.pymol.org: DeLano, W. L. PyMOL, version 0.98; a molecular graphics system; DeLano Scientific LLC: Palo Alto, CA, 2002.